Navigation Links
Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
Date:7/17/2008

Highlights Include Clinical Trial Updates

BETHESDA, Md., July 18 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. (AIM: NWBS and NWBT; OTC Bulletin Board: NWBO), (the "Company or NWBT"), today announced that Dr. Alton L. Boynton, its President and Chief Executive Officer, will deliver a presentation updating the Company's progress in the development of dendritic vaccines for the treatment of cancer, at the "Next Generation Vaccines" conference. The conference will be held on 17 &18 July, at the Gaylord National Resort and Convention Center in National Harbor, Maryland, USA. Dr. Boynton is scheduled to present as part of the Advances in Cancer Vaccines session on July 18th @ 11:15 am EST.

Dr. Boynton will provide an update on NWBT's product candidates, including therapeutic cancer vaccines DCVax(R)-Brain for the treatment of Glioblastoma multiforme and DCVax(R)-Prostate for hormone-independent prostate cancer.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines and therapeutic antibodies. The Company is currently conducting a large Phase II clinical trial in GBM, which is designed and powered to serve as a pivotal trial. The Company has also received clearance from the FDA for a large Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. The Company has started a Phase I/II trial with DCVax(R) directed to ovarian cancer. The Company's second technology platform, involving antibodies to CXCR4, is at the late pre-clinical development stage.

For further information, please visit the company web site at http://www.nwbio.com

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in the Phase II trial of DCVax(R)-Brain and complete the trial on a timely basis, risks related to meeting the clinical endpoints in the planned Phase II clinical trial of DCVax(R)-Brain, risks related to manufacturing, risks related to the Company's ability to initiate, and enroll patients in, the planned Phase III trial of DCVax(R)-Prostate and complete the trial on a timely basis, the uncertainty of the clinical trials process and whether DCVax(R)-Prostate or DCVax(R)-Brain will demonstrate safety and efficacy, and the timely performance of third parties. Additional information on these and other factors, which could affect the Company's results, is included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.


'/>"/>
SOURCE Northwest Biotherapeutics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Northwestern chemist investigates lost reds in Homer painting
2. Nikon Instruments Opens New Imaging Center at Northwestern University
3. Northwest Secures US$4.0 Million in Debt Financing
4. Cell Therapeutics, Inc. (CTI) Invest Northwest Presentation to be Webcast
5. Cell Therapeutics, Inc. (CTI) to Present at 7th Annual WBBA Invest Northwest Conference
6. Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics
7. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
8. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
9. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
10. Protalix BioTherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel
11. Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... ... variety of fracture-specific plating options designed to address fractures of the distal tibia ... solutions. , The Acumed Ankle Plating System 3 is composed of seven plate ...
(Date:5/25/2016)... ... ... Lady had been battling arthritis since the age of two and at ... owner Hannah sought the help of Dr Jeff Christiansen of Superior Veterinary Surgical ... and help with the pain of Lady’s arthritis. Dr Christiansen suggested that in conjunction ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... re-branded identity. The new Media Cybernetics corporate branding reflects a results-driven revitalization for ... and image analysis. The re-branding components include a crisp, refreshed logo and a ...
(Date:5/23/2016)... , May 23, 2016 - Leading CRO,s ... - Frontage Implement a Single Platform to Manage End-to-end ... Traceability Within the Bioanalytical lab Frontage Laboratories, a full-service ... States and China , has selected ... facilities. In addition to serving as the global electronic lab notebook ...
Breaking Biology Technology:
(Date:3/18/2016)... March 18, 2016 --> ... Biometrics, ICT, Manned & Unmanned Vehicles, Physical infrastructure and Perimeter ... companies in the border security market and the continuing migration ... Europe has led visiongain to publish ... success. --> defence & security companies in ...
(Date:3/14/2016)... http://www.apimages.com ) - ... - Renvoi : image disponible via AP Images ( ... --> DERMALOG, le leader de l,innovation ... d,empreintes digitales pour l,enregistrement des réfugiés en Allemagne. ... produire des cartes d,identité aux réfugiés. DERMALOG dévoilera ...
(Date:3/9/2016)... This BCC Research report provides an overview ... Sequencing (RNA Seq) market for the years 2015, 2016 ... reagents, data analysis, and services. Use this ... market such as RNA-Sequencing tools and reagents, RNA-Sequencing data ... each segment and forecast their market growth, future trends ...
Breaking Biology News(10 mins):